Our Mission:
Improving the quality of life of myeloma patients while working toward prevention and a cure
I am a...
About Multiple Myeloma
Multiple myeloma starts in the bone marrow plasma cells. It weakens the immune system and can affect many parts of the body by causing the bone marrow to create dysfunctional antibodies and plasma cells. Living with or treating this disease means making complicated decisions, and this requires searching for reliable, current information on multiple myeloma.
How Can the International Myeloma Foundation Help?
The International Myeloma Foundation (IMF) connects people to what matters most — research that pushes the field forward, education that clarifies complex topics, support tailored to individual needs, and advocacy that amplifies every voice. Patients, care partners, healthcare professionals, and researchers can access the knowledge, resources, and community they need from the IMF to navigate life with myeloma.
This week’s blog is a republication of IMF Chief Medical Officer Dr. Joseph Mikhael's Myeloma Today article on the 2025 Latin American Myeloma Network (LAMN) Master Class and Summit. It also discusses the 2025 IMF LAMN Master Class and Summit, which took place on November 14-15, 2025, in Santiago, Chile — demonstrating a strong sense of optimism for what the IMF LAMN can accomplish in the region. READ THE BLOG.
On March 5, 2026, the U.S. Food and Drug Administration (FDA) approved teclistamab in combination with daratumumab hyaluronidase-fihj (Tec-Dara) for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least one prior line of therapy. The decision follows results from the MajesTEC-3 trial, where Tec-Dara reduced the risk of disease progression or death by 83% compared with standard treatment. LEARN MORE.
El próximo Grupo de Apoyo Las Voces del Mieloma se llevará a cabo el martes 17 de marzo de 2026, de 10:00 a. m. a 11:00 a. m. (hora del Pacífico). El orador invitado será el Dr. Jesús G. Berdeja, MD, Director de Investigación sobre Mieloma Múltiple en los Centros Greco-Hainsworth para la Investigación del Cáncer de Tennessee Oncology en Nashville. Graduado de Stanford y Harvard con formación en hematología y oncología de Johns Hopkins, es miembro del Grupo de Trabajo Internacional sobre Mieloma de la IMF y ha sido investigador principal en numerosos ensayos clínicos, además de tener numerosas publicaciones sobre el tema. El Dr. Berdeja hablará sobre Terapias de Redireccionamiento de Células T en el Tratamiento del Mieloma Múltiple: Actualizaciones de ASH 2025. Si tiene alguna pregunta, envíe un correo electrónico a [email protected]. REGÍSTRESE AQUÍ.
The next Las Voces de Mieloma Support Group will be on Tuesday, March 17, 2026, from 10 a.m. - 11 a.m. PST. The meeting's Guest Speaker will be Dr. Jesus G. Berdeja, MD, who is the Director of Multiple Myeloma Research at the Greco-Hainsworth Centers for Cancer Research at Tennessee Oncology in Nashville. A Stanford and Harvard graduate with hematology-oncology training from Johns Hopkins, he is an IMF International Myeloma Working Group Member, and he has served as principal investigator on numerous trials as well as published extensively in the field. Dr. Berdeja will speak about T-Cell Redirecting Therapies in the Treatment of Multiple Myeloma: Updates from ASH 2025. For any questions, please email [email protected]. REGISTER HERE.
The IMF will host a Living Well with Myeloma webinar on Tuesday, March 10, 2026, at 4:00 p.m. PST | 7:00 p.m. EST. Karen Wonders, PhD, Founder and CEO of Maple Tree Cancer Alliance, and Professor and Program Director of Exercise Physiology at Wright State University, will speak about movement for myeloma patients and their care partners. REGISTER NOW.
Need assistance in creating a fundraiser? The IMF team is here for you. Find out how you can help in the fight against myeloma today!
